Enliven Therapeutics (ELVN) Other Non-Current Liabilities (2022 - 2025)

Enliven Therapeutics has disclosed Other Non-Current Liabilities across 4 years of filings, most recently posting $103000.0 for Q3 2025.

• Other Non-Current Liabilities for Q3 2025 came in at $103000.0, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $103000.0 (changed N/A YoY), and the FY2023 annual result was $67000.0, down 89.83% from the prior year.
• Other Non-Current Liabilities came in at $103000.0 for Q3 2025 at Enliven Therapeutics, down from $204000.0 in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $659000.0 in Q4 2022 to a low of $6000.0 in Q2 2024.
• The 4-year median for Other Non-Current Liabilities is $209000.0 (2023), against an average of $245700.0.
• Across the five-year window, Other Non-Current Liabilities plunged 98.33% in 2024 and soared 3300.0% in 2025, its largest moves.
• Enliven Therapeutics' Other Non-Current Liabilities stood at $659000.0 in 2022, then tumbled by 89.83% to $67000.0 in 2023, then plunged by 91.04% to $6000.0 in 2024, then jumped by 1616.67% to $103000.0 in 2025.
• The last three Other Non-Current Liabilities figures came in at $103000.0 (Q3 2025), $204000.0 (Q2 2025), and $302000.0 (Q1 2025), per Business Quant data.